Systemic Anti-Cancer Therapy Regimen Library
BR Metastatic - PACLItaxel nanoparticle albumin bound [Abraxane] [Q1W 2/3] and pembrolizumab Q3W
Treatment Overview
Continue until disease progression or unacceptable toxicity (up to 2 years for pembrolizumab).
Cycle 1 (and all further cycles) - 21 days
Cycle details
Cycle 1 (and all further cycles) - 21 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| ondansetron * | 8 mg | oral administration | 1, 8 | |
| pembrolizumab | 200 mg flat dosing | intravenous | 1 | 30 minutes |
| PACLItaxel nanoparticle albumin bound * | 100 mg/m² | intravenous | 1, 8 | 30 minutes |
| domperidone | 10 mg Three times daily | oral administration | 1 |
Full details
Cycle 1 (and all further cycles) - 21 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| ondansetron * | 8 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy.
|
|
| pembrolizumab | 200 mg flat dosing | intravenous | 30 minutes |
Instructions:
Administer via a sterile, non-pyrogenic, low protein binding 0.2 to 5 micron in-line or add-on filter. |
| PACLItaxel nanoparticle albumin bound * | 100 mg/m² | intravenous | 30 minutes |
Instructions:
Do not administer via an in-line filter with a pore size of less than 15 micron. |
| domperidone | 10 mg Three times daily | oral administration |
Instructions:
When required for nausea and/or vomiting.
|
Day: 8
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| ondansetron * | 8 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy.
|
|
| PACLItaxel nanoparticle albumin bound * | 100 mg/m² | intravenous | 30 minutes |
Instructions:
Do not administer via an in-line filter with a pore size of less than 15 micron. |
Supportive Care Factors
| Factor | Value |
|---|---|
| Emetogenicity: | Low |
| Hypersensitivity / Infusion related reaction risk: | Low - routine premedication not recommended |
References
Bristol-Myers Squibb (NZ) Limited. Abraxane New Zealand Data Sheet 24 January 2025. https://www.medsafe.govt.nz/profs/datasheet/a/Abraxaneinj.pdf (Accessed 27 May 2025).
Merck Sharp & Dohme (New Zealand) Limited. Keytruda New Zealand Data Sheet 29 April 2025. https://www.medsafe.govt.nz/profs/Datasheet/k/Keytruda.pdf (Accessed 27 May 2025).
Regimen details sometimes vary slightly from the published literature after recommendation by expert committee consensus.
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.